U.S. Markets close in 3 hrs 29 mins

Cardiovascular Systems to Webcast Fiscal 2017 Second-Quarter Earnings Conference Call Wednesday, January 25

ST. PAUL, Minn.--(BUSINESS WIRE)--

Cardiovascular Systems, Inc. (CSI) (CSII) will host a live webcast of its fiscal 2017 second-quarter conference call on Wednesday, January 25, 2017, at 3:45 p.m. CT (4:45 p.m. ET). Scott Ward, Chairman, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company’s results for its fiscal second quarter ended December 31, 2016, and its financial outlook. The company will issue a post-market earnings release prior to the call on January 25.

To access the live webcast, go to the events section of the company’s investor relations website, http://investors.csi360.com/Investors/Events, on the day of the conference call and click on the webcast link. A webcast replay will be available beginning at 6:45 p.m. CT the same day.

To participate in the conference call, dial (877) 201-0168 and enter 47648849. Please dial in at least 10 minutes prior to the call.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (855) 859-2056 and enter 47648849. The audio replay will be available beginning at 6:45 p.m. CT on Wednesday, January 25, 2017, through 10:59 p.m. CT on Wednesday, February 1, 2017.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted the first 510(k) clearance for the use of the Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the Coronary Orbital Atherectomy System. To date, over 275,000 of CSI’s devices have been sold to leading institutions across the United States. For more information, visit the company’s website at www.csi360.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005973/en/